Updated Efficacy and Safety Data from the Phase 2 NP28761 Study of Alectinib in ALK-Positive Non-Small-Cell Lung Cancer

被引：8

作者：

Camidge, D. Ross ^{[1
]}

Gadgeel, Shirish ^{[2
]}

Ou, Sai-Hong ^{[3
]}

Gandhi, Leena ^{[4
]}

Riely, Gregory ^{[5
]}

Cetnar, Jeremy ^{[6
]}

West, Howard ^{[7
]}

Socinski, Mark ^{[8
]}

Chiappori, Alberto ^{[9
]}

Mekhail, Tarek ^{[10
]}

Chao, Bo ^{[11
]}

Borghaei, Hossein ^{[12
]}

Gold, Kathryn ^{[13
]}

Bordogna, Walter ^{[14
]}

Balas, Bogdana ^{[14
]}

Noe, Johannes ^{[14
]}

Golding, Sophie ^{[14
]}

Zeaiter, Ali ^{[14
]}

Shaw, Alice ^{[15
]}

机构：

[1] Univ Colorado, Aurora, CO USA

[2] Wayne State Univ, Karmanos Canc Inst, Detroit, MI USA

[3] Univ Calif Irvine, Sch Med, Orange, CA 92668 USA

[4] Dana Farber Canc Inst, Boston, MA 02115 USA

[5] Mem Sloan Kettering Canc Ctr, 1275 York Ave, New York, NY 10021 USA

[6] Oregon Hlth & Sci Univ, Portland, OR 97201 USA

[7] Swedish Canc Inst, Seattle, WA USA

[8] Univ Pittsburgh, Med Ctr, Pittsburgh, PA USA

[9] H Lee Moffitt Canc Ctr & Res Inst, Tampa, FL USA

[10] Florida Hosp, Canc Inst, Orlando, FL USA

[11] Ohio State Univ, Columbus, OH 43210 USA

[12] Fox Chase Canc Ctr, 7701 Burholme Ave, Philadelphia, PA 19111 USA

[13] Univ Texas MD Anderson Canc Ctr, Thorac Med Oncol, Houston, TX 77030 USA

[14] F Hoffmann La Roche, Basel, Switzerland

[15] Massachusetts Gen Hosp, Boston, MA 02114 USA

来源：

JOURNAL OF THORACIC ONCOLOGY | 2017年 / 12卷 / 01期

关键词：

Alectinib; NSCLC; US; ALK-inhibitor;

D O I：

10.1016/j.jtho.2016.11.426

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

MA07.02

引用

页码：S378 / S378

页数：1

共 50 条

[21] Safety and effectiveness of alectinib in a real-world surveillance study in patients with ALK-positive non-small-cell lung cancer in Japan
Masuda, Noriyuki
Ohe, Yuichiro
Gemma, Akihiko
Kusumoto, Masahiko
Yamada, Ikuyo
Ishii, Tadashi
Yamamoto, Nobuyuki
CANCER SCIENCE, 2019, 110 (04) : 1401 - 1407
[22] Updated efficacy and safety from the global phase II NP28673 study of alectinib in patients (pts) with previously treated ALK plus non-small-cell lung cancer (NSCLC)
Barlesi, F.
Dingemans, A-M. C.
Yang, J. C-H.
Ou, S-H. I.
Ahn, J. S.
De Petris, L.
Hughes, B.
Lena, H.
Bordogna, W.
Golding, S.
Morcos, P. N.
Balas, B.
Zeaiter, A.
Kim, D-W.
ANNALS OF ONCOLOGY, 2016, 27
[23] Efficacy and safety of alectinib in ALK-positive non-small cell lung cancer and blood markers for prognosis and efficacy: a retrospective cohort study
Jiang, Yingying
Shi, Yue
Liu, Yiling
Wang, Zihan
Ma, Yuxin
Shi, Xinhong
Lu, Lin
Wang, Zhitong
Li, Hang
Zhang, Yushu
Liu, Caolu
Zhang, Shaorui
Zhong, Zhihao
Lu, Jianwei
Shi, Meiqi
Shen, Bo
Zhou, Guoren
Yin, Rong
Galetta, Domenico
Grenda, Anna
Romero, Atocha
Hughes, Brett G. M.
Chen, Cheng
Wang, Xiaohua
Feng, Jifeng
TRANSLATIONAL LUNG CANCER RESEARCH, 2022, 11 (12) : 2521 - 2538
[24] Lorlatinib in patients with ALK-positive non-small-cell lung cancer: results from a global phase 2 study
Solomon, Benjamin J.
Besse, Benjamin
Bauer, Todd M.
Felip, Enriqueta
Soo, Ross A.
Camidge, D. Ross
Chiari, Rita
Bearz, Alessandra
Lin, Chia-Chi
Gadgeel, Shirish M.
Riely, Gregory J.
Tan, Eng Huat
Seto, Takashi
James, Leonard P.
Clancy, Jill S.
Abbattista, Antonello
Martini, Jean-Francois
Chen, Joseph
Peltz, Gerson
Thurm, Holger
Ou, Sai-Hong Ignatius
Shaw, Alice T.
LANCET ONCOLOGY, 2018, 19 (12): : 1654 - 1667
[25] Chinese perspectives on clinical efficacy and safety of alectinib in patients with ALK-positive advanced non-small cell lung cancer
Yu, Hui
Sun, Si
Hu, Xingjiang
Xia, Jinjing
Wang, Jialei
Chen, Haiquan
ONCOTARGETS AND THERAPY, 2019, 12 : 6481 - 6495
[26] Indirect comparisons of brigatinib and alectinib for front-line ALK-positive non-small-cell lung cancer
Reckamp, Karen L.
Lin, Huamao M.
Cranmer, Holly
Wu, Yanyu
Zhang, Pingkuan
Walton, Laura J.
Kay, Stephen
Cichewicz, Allie
Neupane, Binod
Fahrbach, Kyle
Popat, Sanjay
Camidge, D. Ross
FUTURE ONCOLOGY, 2022, 18 (20) : 2499 - 2510
[27] Updated Efficacy and Safety of Lorlatinib in a Phase 2 Study in Chinese Patients With Previously Treated Advanced ALK-Positive Non-small Cell Lung Cancer
Lu, Shun
Zhou, Qing
Liu, Xiaoqing
Du, Yingying
Fan, Yun
Cheng, Ying
He, Shan
Zhao, Huadong
Li, Heyan
Wu, Yi-Long
CLINICAL LUNG CANCER, 2024, 25 (07)
[28] Brigatinib effective in ALK-positive non-small-cell lung cancer
Das, Manjulika
LANCET ONCOLOGY, 2017, 18 (06): : E310 - E310
[29] Phase II Trial of the Combination of Alectinib with Bevacizumab in Alectinib Refractory ALK-Positive Nonsquamous Non-Small-Cell Lung Cancer (NLCTG1501)
Watanabe, Satoshi
Sakai, Kazuko
Matsumoto, Naoya
Koshio, Jun
Ishida, Akira
Abe, Tetsuya
Ishikawa, Daisuke
Tanaka, Tomohiro
Aoki, Ami
Kajiwara, Tomosue
Koyama, Kenichi
Miura, Satoru
Goto, Yuka
Sekiya, Tomoki
Suzuki, Ryo
Kushiro, Kohei
Fujisaki, Toshiya
Yanagimura, Naohiro
Ohtsubo, Aya
Shoji, Satoshi
Nozaki, Koichiro
Saida, Yu
Yoshizawa, Hirohisa
Nishio, Kazuto
Kikuchi, Toshiaki
CANCERS, 2023, 15 (01)
[30] Alectinib in ALK-positive, crizotinib-resistant, non-small-cell lung cancer: a single-group, multicentre, phase 2 trial
Shaw, Alice T.
Gandhi, Leena
Gadgeel, Shirish
Riely, Gregory J.
Cetnar, Jeremy
West, Howard
Camidge, D. Ross
Socinski, Mark A.
Chiappori, Alberto
Mekhail, Tarek
Chao, Bo H.
Borghaei, Hossein
Gold, Kathryn A.
Zeaiter, Ali
Bordogna, Walter
Balas, Bogdana
Puig, Oscar
Henschel, Volkmar
Ou, Sai-Hong Ignatius
LANCET ONCOLOGY, 2016, 17 (02): : 234 - 242

← 1 2 3 4 5 →